RE:Solid weekPersonally, if the SP is not well above $4 by the end of October, then BC is turning out to be a flop. It will have been almost a year since it was ready for market and if after a year a pandemic tool is not selling during a pandemic, it ain't gonna look a heck of a lot better after the pandemic IMO. So, the current rise does not impress me given the journey of the past year. It just sucks less for the Biocloud investors, and partly due to the core business.